NasdaqGM:WVEPharmaceuticals
Will Regaining Full Rights to WVE-006 and Pursuing FDA Fast Track Change Wave Life Sciences' (WVE) Narrative
In early February 2026, Wave Life Sciences announced it had regained full global rights to WVE-006, its investigational GalNAc-conjugated RNA editing therapy for the rare genetic condition alpha-1 antitrypsin deficiency, from GSK and is now accelerating its US regulatory plans, including discussions on a potential FDA accelerated approval pathway.
An important implication is that Wave now retains all future economics for WVE-006 in alpha-1 antitrypsin deficiency while still maintaining a...